SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma informs about ESG rating

27 Oct 2025 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, Marksans Pharma has informed that as per information received by the undersigned from BSE, CFC Finlease, a SEBI Licensed ESG Rating Provider (ERP), has voluntarily reviewed the ESG rating on the Company, based on data available in public domain for the Fiscal 2025, and assigned an ESG Score of ‘73’. The same can be accessed at https://www.bseindia.com/stock-share-price/marksans-pharmaltd/marksans/524404/intermediaries-ERP/.

The above information is a part of company’s filings submitted to BSE.  

Marksans Pharma Share Price

178.65 3.60 (2.06%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×